JPRN-UMIN000012122已完成1 期
Phase I/II study of bendamustine, fludarabine and cyclophosphamide conditioning for allogeneic stem cell transplantation in refractory follicular lymphoma (KSGCT1301 / FL benda) - KSGCT1301 / FL benda
Kanto Study Group for Cell Therapy (KSGCT)0 个研究点目标入组 35 人开始时间: 2013年11月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients should not have controllable disease by chemotherapy (2) Uncontrolled diabetes mellitus (3) Uncontrolled hypertension (4) Active infection (5) Positive for TPHA, HBs Ag, HBe Ag, or HCV Ab (6) Positive for HIV Ab (7) Patients should be expected that they survive over 100 days after transplantation. (8) Patients should not have other active malignant diseases. (9) Pregnant or nursing women (10) Mental disorder (11) Previous allogeneic transplantation (12) Other inappropriate symptoms
研究者
相似试验
已完成
2 期
Phase II study of bendamustine, rituximab and cytarabine for patients with relapsed or refractory follicular lymphoma or mantle cell lymphomarelapsed or refractory follicular lymphoma or mantle cell lymphomaJPRN-UMIN000009797Gifu University Hospital13
进行中（未招募）
1 期
Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation. - Bendamustine and Temsirolimus in relapsed or refractory mantle cell lymphomaEUCTR2009-014844-13-DECharité Universitätsmedizin Berlin20
招募中
1 期
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaJPRN-UMIN000005428Department of Hematology, International Medical Center, Saitama Medical University40
招募中
1 期
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of elderly relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000006513Kinki University School of Medecine Division of Hematology43
进行中（未招募）
不适用
Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukemia - BEN-CAMEUCTR2008-001824-30-ITAssociazione Malattie Sangue Onlus